TAMSULOSIN HYDROCHLORIDE | A078225 | ZYDUS PHARMACEUTICALS USA INC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Amendment to Suitability Petition from Rising Pharma Holdings, Inc. FDA-2026-P-3630 · 6 docket documents Rising Pharma Holdings, Inc. submitted an amendment to its suitability petition FDA-2026-P-3630 on April 28, 2026, providing the reference listed drug product labeling for FLOMAX and proposed product labeling for Tamsulosin Hydrochloride Capsules, USP 0.8 mg in response to the FDA's April 20, 2026 i | Suitability | 2026-04-28 | Open | Rising Pharma Holdings, Inc. |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$0.0495
per ea
Lowest NADAC/Unit
$0.0495
per ea
Brand NDCs
0
Generic NDCs
6
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 68382013201TAMSULOSIN HCL 0.4 MG CAPSULE | $0.0495 | EA | Generic | — | 2026-06-17 |
| 68382013210TAMSULOSIN HCL 0.4 MG CAPSULE | $0.0495 | EA | Generic | — | 2026-06-17 |
| 68382013216TAMSULOSIN HCL 0.4 MG CAPSULE | $0.0495 | EA | Generic | — | 2026-06-17 |
| 82009002510TAMSULOSIN HCL 0.4 MG CAPSULE | $0.0495 | EA | Generic | — | 2026-06-17 |
| 68084029901TAMSULOSIN HCL 0.4 MG CAPSULE | $0.0495 | EA | Generic | — | 2026-06-17 |
| 68084029965TAMSULOSIN HCL 0.4 MG CAPSULE | $0.0495 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.